Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “ALK”

444 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 444 results

Not applicableUnknownNCT03820154
What this trial is testing

Diagnostic Equivalence of the Skin Prick Test Tape vs. Conventional Skin PrickTest

Who this might be right for
Allergic RhinitisAllergic AsthmaAllergic Conjunctivitis+1 more
Prof. Dr. Claus Bachert BVBA 75
Large-scale testing (Phase 3)Study completedNCT02604342
What this trial is testing

Alectinib Versus Pemetrexed or Docetaxel in Anaplastic Lymphoma Kinase (ALK)-Positive Advanced Non-Small Cell Lung Cancer (NSCLC) Participants Previously Treated With Platinum-Based Chemotherapy and Crizotinib

Who this might be right for
Non-small Cell Lung Cancer
Hoffmann-La Roche 119
Testing effectiveness (Phase 2)Looking for participantsNCT05950139
What this trial is testing

Peptide Vaccine To Prevent Acquired Resistance In Patients With Advanced ALK+ NSCLC

Who this might be right for
NSCLC Stage IVALK Fusion Protein Expression
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins 12
Testing effectiveness (Phase 2)Study completedNCT03088930
What this trial is testing

Evaluating Crizotinib in the Neoadjuvant Setting in Patients With Non-small Cell Lung Cancer

Who this might be right for
Lung Cancer, Nonsmall Cell
University of Colorado, Denver 3
Testing effectiveness (Phase 2)Active Not RecruitingNCT03944772
What this trial is testing

Phase 2 Platform Study in Patients With Advanced Non-Small Lung Cancer Who Progressed on First-Line Osimertinib Therapy (ORCHARD)

Who this might be right for
Non-Small Cell Lung Cancer
AstraZeneca 247
Post-approval studies (Phase 4)UnknownNCT02804646
What this trial is testing

Endostar Durative Transfusion Combined With Chemotherapy in the Treatment of Advanced Lung Adenocarcinoma

Who this might be right for
Adenocarcinoma of Lung
Anhui Provincial Hospital 100
Early research (Phase 1)Looking for participantsNCT05544019
What this trial is testing

Study of SGR-1505 in Mature B-Cell Neoplasms

Who this might be right for
Mature B-Cell NeoplasmNon Hodgkin LymphomaDLBCL+23 more
Schrödinger, Inc. 98
Testing effectiveness (Phase 2)Study completedNCT01198665
What this trial is testing

RAD001 Combined With CHOP in Newly Diagnosed Peripheral T-cell Lymphomas

Who this might be right for
Peripheral T Cell Lymphoma UnspecifiedAnaplastic Large Cell Lymphoma, ALK-negativeAngioimmunoblastic T Cell Lymphoma+1 more
Samsung Medical Center 46
Testing effectiveness (Phase 2)Looking for participantsNCT06426511
What this trial is testing

CtDNA-MRD Guided Consolidation Toripalimab in Stage IB-IIIA NSCLC

Who this might be right for
Lung Cancer, Nonsmall Cell
Sun Yat-sen University 80
Early research (Phase 1)Active Not RecruitingNCT04231877
What this trial is testing

Polatuzumab Vedotin and Combination Chemotherapy With or Without Glofitamab for the Treatment of Untreated Aggressive Large B-cell Lymphoma

Who this might be right for
Aggressive Non-Hodgkin LymphomaALK-Positive Large B-Cell LymphomaDiffuse Large B-Cell Lymphoma, Not Otherwise Specified+6 more
University of Washington 56
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07573696
What this trial is testing

Multidisciplinary Treatment of Stage III ALK+ NSCLC With Neoadjuvant Alectinib and Chemotherapy

Who this might be right for
Nonsmall Cell Lung Cancer Stage III
Wen-zhao ZHONG 50
Early research (Phase 1)Ended earlyNCT03087448
What this trial is testing

Ceritinib + Trametinib in Patients With Advanced ALK-Positive Non-Small Cell Lung Cancer (NSCLC)

Who this might be right for
Non-small Cell Lung Cancer
University of California, San Francisco 9
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07330076
What this trial is testing

Iruplinalkib Tablets as Postoperative Adjuvant Therapy in Stage IA ALK-positive NSCLC With High-risk Factors

Who this might be right for
NSCLC
Tianjin Medical University Cancer Institute and Hospital 28
Testing effectiveness (Phase 2)Study completedNCT02223208
What this trial is testing

Ro Plus CHOEP as First Line Treatment Before HSCT in Young Patients With Nodal Peripheral T-cell Lymphomas

Who this might be right for
Peripheral T-cell Lymphomas (PTCL)PTCL-NOSAngioimmunoblastic T-cell Lymphoma (AITL)+2 more
Fondazione Italiana Linfomi - ETS 89
Large-scale testing (Phase 3)Looking for participantsNCT07300514
What this trial is testing

Golidocitinib Versus Placebo as Maintenance Therapy for Peripheral T-Cell Lymphoma

Who this might be right for
Maintenance Treatment of Peripheral T-cell Lymphoma
Fudan University 136
Not applicableEnrolling By InvitationNCT07122882
What this trial is testing

Integrated Genomics in Oncogene-driven NSCLC With Acquired Resistance

Who this might be right for
Oncogene-addicted Non Small Cell Lung CancerEGFR MutationALK Fusion-positive Solid or CNS Tumors+10 more
Chang Gung Memorial Hospital 40
Large-scale testing (Phase 3)Study completedNCT01951482
What this trial is testing

Pemetrexed/Platinum With or Without Bevacizumab in Brain Metastases From Patients With EGFR/ALK Negative Non-Squamous Non-small Cell Lung Cancer

Who this might be right for
Non Squamous Non-small Cell Lung CancerBrain MetastasesBevacizumab
Sun Yat-sen University 160
Testing effectiveness (Phase 2)Ended earlyNCT03131206
What this trial is testing

Alectinib in RET-rearranged Non-small Cell Lung Cancer or RET-mutated Thyroid Cancer

Who this might be right for
ALK-positive Non-small Cell Lung Cancer (NSCLC)RET-positive Non-small Cell Lung Cancer (NSCLC)RET-positive Thyroid Cancer
Dana-Farber Cancer Institute 5
Testing effectiveness (Phase 2)Looking for participantsNCT03093116
What this trial is testing

Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements

Who this might be right for
Locally Advanced Solid TumorsMetastatic Solid Tumors
Turning Point Therapeutics, Inc. 500
Not applicableStudy completedNCT03603847
What this trial is testing

Prospective Study of the Prognostic Value of New Markers in Adults With ALK-positive Large Anaplastic Lymphoma

Who this might be right for
Anaplastic Large Cell Lymphoma, ALK-Positive
The Lymphoma Academic Research Organisation 41
Next Page